Updated:
Ecphora Capital Management Company
Ecphora Capital is Maryland's premier medtech venture capital firm. Its vision is to establish Maryland as the global epicenter for medical commercialization,...
Ecphora Capital Management Company
Ecphora Capital is Maryland's premier medtech venture capital firm. Its vision is to establish Maryland as the global epicenter for medical commercialization, advancing innovations that transform medicine and healthcare. The firm focuses on medical devices, biotech, digital health, and healthtech, and is led by Deborah Hemingway, Ph.D.
General information
Firm type
Private Equity
Year founded
2022
Location
Region
North America
Country
United States
City
Baltimore
Corporate office
101 W Dickman St, Suite 900, Baltimore, MD 21230, United States
Principals
Deborah Hemingway
Managing Partner
Jeremy Neilson
Managing Director, Head of Operations
Charles Kirby
Venture Partner
Sathya Janardhanan
Venture Partner
Lauren Renz
Director of Investor Relations
Camilo Vanegas
Venture Partner
Sector focus
Frequently asked questions
Who runs investment decisions at Ecphora Capital?
Managing Partner Deborah Hemingway, PhD, leads investment decisions. She is a biophysicist by training and operates as a solo general partner. An extended team of venture partners and a managing director for operations support sourcing, diligence, and portfolio management.
How does Ecphora Capital source proprietary deal flow?
Ecphora relies on exclusive institutional partnerships in the BioHealth Capital Region. It holds first-look access through The LaunchPort medical device accelerator and maintains structured relationships with Johns Hopkins University, the University of Maryland system, the NIH, and NIST. This funnel gives the firm early visibility into medtech innovations emerging from federally funded and academic laboratories.
Does Ecphora Capital participate in fund commitments or only direct deals?
Ecphora makes direct early-stage investments in medtech startups. It also operates SPV Concierge Services, which structures and administers special-purpose vehicles for portfolio companies and external syndicates, but the firm itself deploys capital through its own direct investment vehicle.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: